Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341482 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02341482 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 13 participants.
The verdict
NCT02341482, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
Interventions
- DRUG Itraconazole
- DRUG PF-04958242
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-02-05 |
| Est. Completion | 2015-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341482
The ClinicalTrials.gov registry entry for NCT02341482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT02341482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341482 about?
NCT02341482 is a clinical study titled "A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects". The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
What is the current status of trial NCT02341482?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-02-05. Estimated completion is 2015-03-31.
What interventions are being tested in trial NCT02341482?
The interventions under investigation include: Itraconazole (DRUG), PF-04958242 (DRUG).
Who is sponsoring clinical trial NCT02341482?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.